Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $208.0 million.

  • Ptc Therapeutics' Operating Expenses fell 1723.27% to $208.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 306.95%. This contributed to the annual value of $1.1 billion for FY2024, which is 1945.61% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Operating Expenses stood at $208.0 million, which was down 1723.27% from $213.8 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Operating Expenses peaked at $423.4 million during Q2 2023, and registered a low of $205.9 million during Q1 2025.
  • Its 5-year average for Operating Expenses is $272.3 million, with a median of $251.3 million in 2024.
  • In the last 5 years, Ptc Therapeutics' Operating Expenses skyrocketed by 6416.08% in 2023 and then tumbled by 4639.86% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Operating Expenses (Quarter) stood at $250.0 million in 2021, then soared by 47.13% to $367.8 million in 2022, then fell by 18.09% to $301.2 million in 2023, then rose by 24.67% to $375.6 million in 2024, then plummeted by 44.62% to $208.0 million in 2025.
  • Its last three reported values are $208.0 million in Q3 2025, $213.8 million for Q2 2025, and $205.9 million during Q1 2025.